JP2022518282A5 - - Google Patents

Info

Publication number
JP2022518282A5
JP2022518282A5 JP2021543170A JP2021543170A JP2022518282A5 JP 2022518282 A5 JP2022518282 A5 JP 2022518282A5 JP 2021543170 A JP2021543170 A JP 2021543170A JP 2021543170 A JP2021543170 A JP 2021543170A JP 2022518282 A5 JP2022518282 A5 JP 2022518282A5
Authority
JP
Japan
Prior art keywords
sequence
sequence number
composition
composition according
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021543170A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022518282A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/014845 external-priority patent/WO2020154540A1/en
Publication of JP2022518282A publication Critical patent/JP2022518282A/ja
Publication of JP2022518282A5 publication Critical patent/JP2022518282A5/ja
Priority to JP2024229904A priority Critical patent/JP2025060876A/ja
Withdrawn legal-status Critical Current

Links

JP2021543170A 2019-01-23 2020-01-23 抗cd38結合ドメイン Withdrawn JP2022518282A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024229904A JP2025060876A (ja) 2019-01-23 2024-12-26 抗cd38結合ドメイン

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962795855P 2019-01-23 2019-01-23
US62/795,855 2019-01-23
PCT/US2020/014845 WO2020154540A1 (en) 2019-01-23 2020-01-23 Anti-cd38 antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024229904A Division JP2025060876A (ja) 2019-01-23 2024-12-26 抗cd38結合ドメイン

Publications (2)

Publication Number Publication Date
JP2022518282A JP2022518282A (ja) 2022-03-14
JP2022518282A5 true JP2022518282A5 (enExample) 2023-02-01

Family

ID=69740548

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021543170A Withdrawn JP2022518282A (ja) 2019-01-23 2020-01-23 抗cd38結合ドメイン
JP2024229904A Pending JP2025060876A (ja) 2019-01-23 2024-12-26 抗cd38結合ドメイン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024229904A Pending JP2025060876A (ja) 2019-01-23 2024-12-26 抗cd38結合ドメイン

Country Status (9)

Country Link
US (2) US11414496B2 (enExample)
EP (1) EP3914358A1 (enExample)
JP (2) JP2022518282A (enExample)
CN (1) CN113710324B (enExample)
AR (1) AR119677A1 (enExample)
AU (1) AU2020211407A1 (enExample)
CA (1) CA3127624A1 (enExample)
TW (1) TWI863959B (enExample)
WO (1) WO2020154540A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11414496B2 (en) 2019-01-23 2022-08-16 Takeda Pharmaceutical Company Limited Anti-CD38 binding domains
US11713347B2 (en) 2019-01-23 2023-08-01 Millennium Pharmaceuticals, Inc. CD38-binding proteins comprising de-immunized Shiga toxin A subunit effectors
CA3180690A1 (en) * 2020-06-17 2021-12-23 Ahmed Mahiuddin Cd38 antibodies for treatment of human diseases
AU2023230954A1 (en) * 2022-03-08 2024-10-17 Molecular Templates, Inc. Ctla-4 binding molecules comprising shiga toxin a subunit scaffolds and uses thereof

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
CZ295838B6 (cs) 1996-09-09 2005-11-16 Zealand Pharma A/S Způsob výroby peptidů
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
EP0915987A2 (en) 1997-04-21 1999-05-19 Donlar Corporation POLY-($g(a)-L-ASPARTIC ACID), POLY-($g(a)-L-GLUTAMIC ACID) AND COPOLYMERS OF L-ASP AND L-GLU, METHOD FOR THEIR PRODUCTION AND THEIR USE
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7449443B2 (en) 2000-03-23 2008-11-11 California Institute Of Technology Method for stabilization of proteins using non-natural amino acids
US6586207B2 (en) 2000-05-26 2003-07-01 California Institute Of Technology Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
EP1490677A4 (en) 2002-02-27 2006-01-18 California Inst Of Techn COMPUTER METHOD FOR DESIGNING ENZYMES FOR THE INCORPORATION OF AMINO ACID ANALOGUES INTO PROTEINS
KR20050000380A (ko) 2002-04-09 2005-01-03 교와 핫꼬 고교 가부시끼가이샤 게놈이 개변된 세포
EP1675620B1 (en) 2003-10-09 2019-05-08 Ambrx, Inc. Polymer derivatives
BRPI0507169A (pt) 2004-02-02 2007-06-26 Ambrx Inc polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US7887801B2 (en) 2007-07-13 2011-02-15 Topotarget Germany Ag Optimized DNA and protein sequence of an antibody to improve quality and yield of bacterially expressed antibody fusion proteins
JOP20210044A1 (ar) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
CN111363047A (zh) 2013-03-12 2020-07-03 分子模板公司 用于引起细胞内化的cd20结合免疫毒素及其使用方法
CA2909952C (en) 2013-04-29 2021-10-12 Teva Pharmaceuticals Australia Pty Ltd. Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b
US20160177284A1 (en) * 2014-01-27 2016-06-23 Molecular Templates, Inc. Cell-targeted molecules comprising amino-terminus proximal or amino-terminal shiga toxin a subunit effector regions
ES2749862T3 (es) 2014-01-27 2020-03-24 Molecular Templates Inc Polipéptidos efectores desinmunizados de subunidad A de toxina Shiga para aplicaciones en mamíferos
US9603927B2 (en) * 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US11142584B2 (en) 2014-03-11 2021-10-12 Molecular Templates, Inc. CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same
ES2864124T3 (es) 2014-03-11 2021-10-13 Molecular Templates Inc Proteínas que comprenden regiones de unión, regiones efectoras de la subunidad A de toxina Shiga y motivos señal de localización de retículo endoplasmático carboxi terminal
PT3604333T (pt) * 2014-03-11 2021-06-07 Molecular Templates Inc Proteínas compreendendo regiões efetoras da subunidade a da toxina shiga próximas de amino-terminais e regiões de ligação do tipo imunoglobulina de direcionamento celular capazes de se ligarem especificamente a cd38
KR102496206B1 (ko) 2014-06-11 2023-02-06 몰레큘러 템플레이츠, 인코퍼레이션. 프로테아제-절단 저항성의 시가 독소 a 서브유닛 작동체 폴리펩티드 및 이를 포함하는 세포-표적화 분자
CA2961439A1 (en) 2014-11-05 2016-05-12 Genentech, Inc. Anti-fgfr2/3 antibodies and methods using same
WO2016126950A1 (en) 2015-02-05 2016-08-11 Molecular Templates, Inc. Multivalent cd20-binding molecules comprising shiga toxin a subunit effector regions and enriched compositions thereof
CN114656573B (zh) 2015-05-30 2024-09-27 分子模板公司 去免疫化的志贺毒素a亚基支架和包含它们的细胞靶向分子
MX2018001208A (es) 2015-07-26 2018-03-26 Molecular Templates Inc Moleculas con direccion a las celulas que comprenden efectores de la subunidad a de la toxina shiga y epitopos de celulas-t cd8+.
EP3535291A1 (en) * 2016-11-01 2019-09-11 Genmab B.V. Polypeptide variants and uses thereof
MX2019006656A (es) 2016-12-07 2019-09-09 Molecular Templates Inc Polipeptidos efectores de la sub-unidad a de la toxina shiga andamiajes de los efectores de la toxina shiga y moleculas con direccion hacia las celulas para la conjugacion especifica del sitio.
KR102590672B1 (ko) 2017-01-25 2023-10-18 몰레큘러 템플레이츠, 인코퍼레이션. 탈면역된 시가 독소 a 서브유닛 이펙터 및 cd8+ t-세포 에피토프를 포함하는 세포-표적화 분자
JP7201599B2 (ja) 2017-02-28 2023-01-10 中外製薬株式会社 プロテインlを用いたタンパク質精製
US11713347B2 (en) 2019-01-23 2023-08-01 Millennium Pharmaceuticals, Inc. CD38-binding proteins comprising de-immunized Shiga toxin A subunit effectors
US11414496B2 (en) 2019-01-23 2022-08-16 Takeda Pharmaceutical Company Limited Anti-CD38 binding domains
CN115769181B (zh) 2021-04-23 2025-10-10 京东方科技集团股份有限公司 一种解锁控制方法、装置、电子设备和计算机可读存储介质

Similar Documents

Publication Publication Date Title
JP7138046B2 (ja) 二特異性抗体基幹
CN110382529B (zh) 工程化的异源二聚体蛋白质
TWI359027B (en) Bivalent, bispecific antibodies
JP2019528051A (ja) 修飾抗原結合Fab断片及びこれを含む抗原結合分子
JP7103603B2 (ja) Ch3ドメインに基づくヘテロダイマー分子、その調製方法及び用途
HK1246330A1 (zh) 蛋白质纯化
JP7812230B2 (ja) ポリペプチド鎖交換による抗体由来ポリペプチドの生成
JP2017534296A5 (enExample)
WO2022166728A1 (zh) 双特异性抗体
CN107636012A (zh) 蛋白质纯化方法
JP2024507693A5 (enExample)
JP7638900B2 (ja) 半減期が延長された活性化可能な治療用多重特異性ポリペプチド
JP7688584B2 (ja) ポリペプチド鎖の交換により活性化される治療用多重特異性ポリペプチド
JP2022517549A (ja) 二価の二重特異性抗体およびその製造方法、コードする遺伝子、宿主細胞、組成物
JP2025537782A (ja) 活性化可能なエフェクタードメインを有する組換え結合タンパク質
CN104628851A (zh) 一种抗狂犬病毒的基因工程抗体、其制备方法和应用
JP2025514763A5 (enExample)
Rivera-Castro et al. Comparative analysis of manufacturability and binding of various bispecific antibody architectures
HK40062072B (en) Generation of antibody-derived polypeptides by polypeptide chain exchange
WO2026067827A1 (zh) 一种制备异源多聚体的方法及应用
WO2026059472A1 (en) Bivalent bispecific antibody and method for producing thereof
KR20260065533A (ko) FcRn과 pH 선택적 결합능을 갖는 짧은 펩타이드
JP2025528101A (ja) 多重特異性ポリペプチド複合体
HK40060366B (en) Therapeutic multispecific polypeptides activated by polypeptide chain exchange
HK40064737B (en) Methods for purifying antibodies